Mycobacterium Fortuitum Patents (Class 435/865)
  • Patent number: 7094403
    Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: August 22, 2006
    Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.
    Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
  • Patent number: 6835559
    Abstract: A process for producing an optical active &bgr;-amino alcohol, the method comprising the step of allowing at least one microorganism selected from the group consisting of microorganisms belonging to the genus Morganella and others, to act on an enantiomeric mixture of an &agr;-aminoketone or a salt thereof having the general formula (I): to produce an optical active &bgr;-amino alcohol with the desired optical activity having the general formula (II) described below in a high yield as well as in a highly selective manner:
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: December 28, 2004
    Assignee: Daiichi Fine Chemical Co., Ltd.
    Inventors: Keiji Sakamoto, Shinji Kita, Kazuya Tsuzaki, Tadanori Morikawa, Sakayu Shimizu, Michihiko Kataoka
  • Patent number: 6821769
    Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: November 23, 2004
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
  • Patent number: 6752994
    Abstract: A mutated mycobacterium selected from the class consisting of mutated M. bovis-BCG, mutated M. tuberculosis, and mutated M. leprae. The mutation of M. bovis-BCG, M. tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: June 22, 2004
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam
  • Patent number: 6566121
    Abstract: A mutated mycobacterium selected from the class consisting of mutated M.bovis-BCG, mutated M.tuberculosis, and mutated M. leprae. The mutation of M.bovis-BCG, M.tuberculosis, or M. leprae is preferably effected through an insertional mutation of a mycobacterial gene. The insertional mutagenesis may be effected, for example, through illegitimate recombination or by a mycobacterial transposon. Such mutated mycobacteria may then be transformed with an expression vector(s) containing a complement gene to the gene which is mutated, and preferably also including a heterologous gene.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: May 20, 2003
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: William R. Jacobs, Jr., Barry Bloom, Ganjam V. Kalpana, Jeffrey D. Cirillo, Ruth McAdam
  • Patent number: 6517845
    Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: February 11, 2003
    Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.
    Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
  • Patent number: 6268201
    Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.
    Type: Grant
    Filed: October 23, 1998
    Date of Patent: July 31, 2001
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: David Alland, Barry R. Bloom, William R. Jacobs, Jr.
  • Patent number: 6229001
    Abstract: The invention relates to the nucleic acid sequence and amino acid sequence of dihydrofolate reductase (DHFR) from mycobacteria and to expression of recombinant DHFR protein. Utilizing the recombinant protein, novel therapies and diagnostic strategies can be developed and selective antimycobacterial compositions can be designed and utilized to treat mycobacterial infections in patients. This invention includes all or portions of novel recombinant nucleic acids encoding DHFR for mycobacteria such as M. avium, to novel recombinant DHFR peptides produced by such sequences, and to vaccines, diagnostic kits, cells and therapies utilizing these peptides and nucleic acid sequences. The present invention relates to methods for using the sequences of the present invention to develop drugs specific to M. avium and other mycobacteria, to identify and sequence corresponding sequences in species other than M. avium, as well as diagnostic and treatment methods incorporating the disclosed sequences and peptides.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: May 8, 2001
    Assignee: Southern Research Institute
    Inventors: William W. Barrow, Sabrina Z. Van Ginkel, Thomas P. Dooley, William J. Suling
  • Patent number: 6004771
    Abstract: A method for the preparation of Mycobacteria from any liquid, semi solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.
    Type: Grant
    Filed: August 11, 1997
    Date of Patent: December 21, 1999
    Assignee: Integrated Research Technology, LLC
    Inventor: Charles G. Thornton
  • Patent number: 5994346
    Abstract: Exochelins can be used to prevent damage to organs for transplant from the formation or presence of the .circle-solid.OH radical. In particular, the invention is directed to the administration of exochelins to the organ prior to or coincidental with removal from a donor, storage, implantation in a recipient or in conjunction with reestablishment of flow of body fluids to the organ.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: November 30, 1999
    Assignee: Regents of the University of California
    Inventors: Marcus A. Horwitz, Lawrence D. Horwitz
  • Patent number: 5837677
    Abstract: The invention is directed toward the use of desferri-Exochelins to destroy cancer cells or retard or eliminate the growth of those cancer cells.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 17, 1998
    Assignee: Keystone Biomedical, Inc.
    Inventors: Lawrence D. Horwitz, Kathryn B. Horwitz
  • Patent number: 5837480
    Abstract: This invention relates to InhA enzyme crystals and to methods of growing said crystals. This invention is further directed to the utilization of said crystals to determine the three dimensional structure of InhA enzyme utilizing heavy atom derivatives of said crystals, and to the identification and development of compounds which inhibit the biochemical activity of InhA enzyme in bacteria and plants.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: November 17, 1998
    Assignee: Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: James Sacchettini, John Blanchard, William R. Jacobs, Jr.
  • Patent number: 5830475
    Abstract: The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 3, 1998
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Anna Aldovini, Richard A. Young
  • Patent number: 5721209
    Abstract: Exochelins can be used to prevent damage to living tissue from the formation or presence of the (.cndot.OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins as well as other applications of these materials in the treatment and diagnosis of disease in mammals.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: February 24, 1998
    Assignee: The Regents of the University of California
    Inventors: Lawrence D. Horwitz, Marcus A. Horwitz, Bradford W. Gibson, Joseph Reeve
  • Patent number: 5658749
    Abstract: A method for the preparation of Mycobacteria from any liquid, semi-solid or exotic source is described. The extracted Mycobacterial sample is suitable for detection by culture and amplification.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: August 19, 1997
    Assignee: Corning Clinical Laboratories, Inc.
    Inventor: Charles G. Thornton
  • Patent number: 5523214
    Abstract: A method of visually demonstrating the growth of such microorganisms as fungi, yeasts, and bacteria, especially mycobacteria, identifying them, and testing them for sensitivity to antibiotics by the color change of a specific redox indicator system. A mixture of the redox indicators Methylene Blue and resazurin is added to the culture medium. Iron(III) salts mixed with K.sub.3 Fe(CN).sub.6, Iron(II) salts mixed with K.sub.4 Fe(CN).sub.6, or sodium tungstate (Na.sub.2 WO.sub.4) is added to the culture medium.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: June 4, 1996
    Assignee: Biotest Aktiengesellschaft
    Inventor: Jurgen Horn
  • Patent number: 5516649
    Abstract: A process for the production of 4-androstene-3,17-dione and 1,4-androstadiene-3,17-dione of the general formula ##STR1## wherein . . . . . symbolizes a single bond or a double bond, characterized in that ergosterol ##STR2## is fermented with a culture of a microorganism strain capable of side-chain degradation of sterols.
    Type: Grant
    Filed: June 28, 1994
    Date of Patent: May 14, 1996
    Assignee: Schering Aktiengesellschaft
    Inventors: Alfred Weber, Mario Kennecke
  • Patent number: 5472854
    Abstract: A process for the production of 17-oxosteroids by fermentative oxidation of 17.beta.-hydroxy steroids is described, which is characterized in that for the fermentation, a bacterial culture of the species Mycobacterium spec. NRRL B-3805, Mycobacterium spec. NRRL B-3683, Mycobacterium phlei NRRL B-8154 or Mycobacterium fortuitum NRRL B-8153 is used.
    Type: Grant
    Filed: May 17, 1993
    Date of Patent: December 5, 1995
    Assignee: Schering Aktiengesellschaft
    Inventors: Alfred Weber, Mario Kennekke, Uwe Klages, Klaus Nickisch, Ralph Rohde
  • Patent number: 4443541
    Abstract: A process for the microbiological conversion of steroids to (2+)-(7aS) 2,3,7,7-tetrahydro-7a-methyl-(1H)-indene-1,5(6H)-dione, hereinafter referred to as the indenedione.
    Type: Grant
    Filed: June 4, 1982
    Date of Patent: April 17, 1984
    Assignee: The Upjohn Company
    Inventors: John C. Knight, Merle G. Wovcha
  • Patent number: 4429041
    Abstract: The subject invention concerns a novel one-stage fermentation process for making the useful steroid intermediate 9-hydroxy-3-oxo-4,17(20)-pregnadiene-20-carboxylic acid (I). This process is significantly superior to the best prior art process known for making (I).
    Type: Grant
    Filed: May 11, 1981
    Date of Patent: January 31, 1984
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, John C. Knight, Alfred B. Garcia
  • Patent number: 4425429
    Abstract: The subject invention concerns a novel fermentation process for making the novel useful steroid intermediate 9-hydroxy-3-oxo-4,17(20)-pregnadiene-20-carboxyaldehyde (I). This compound can be used as in the synthesis of valuable corticoids.
    Type: Grant
    Filed: July 24, 1981
    Date of Patent: January 10, 1984
    Assignee: The Upjohn Company
    Inventors: John C. Knight, Merle G. Wovcha
  • Patent number: 4423146
    Abstract: The subject invention concerns a novel fermentation process for making the useful steroid intermediate 24-nor-1,4-choladiene-3,22-dione (I). Compound (I) can be converted to valuable corticoids by known methods.
    Type: Grant
    Filed: August 10, 1981
    Date of Patent: December 27, 1983
    Assignee: The Upjohn Company
    Inventors: John C. Knight, Merle G. Wovcha
  • Patent number: 4358538
    Abstract: Mutant which is used in a novel microbiological process to selectively transform steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield sole transformed product. AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: November 9, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Kevin E. Brooks
  • Patent number: 4345034
    Abstract: Mutant which is used in a novel microbiological process to selectively transform steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield androst-4-ene-3,17-dione (AD) as essentially the sole transformed product. AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: August 8, 1980
    Date of Patent: August 17, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Kevin E. Brooks
  • Patent number: 4345033
    Abstract: Mutant which is used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield predominantly androst-4-ene-3,17-dione (AD) and small amounts of androsta-1,4-diene-3,17-dione (ADD). AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: August 17, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs, Thomas R. Pyke
  • Patent number: 4329432
    Abstract: Novel compounds prepared by microbial transformation using novel mutants to selectively degrade steroids with or without 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive. These compounds can be used as intermediates to make useful steroids.
    Type: Grant
    Filed: August 28, 1980
    Date of Patent: May 11, 1982
    Assignee: The Upjohn Company
    Inventors: John C. Knight, Merle G. Wovcha
  • Patent number: 4328315
    Abstract: Mutants which are used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to androsta-1,4-diene-3,17-dione (ADD) and androst-4-ene-3,17-dione (AD). ADD and AD are valuable intermediates to make useful steroids.
    Type: Grant
    Filed: September 8, 1980
    Date of Patent: May 4, 1982
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs, Thomas R. Pyke
  • Patent number: 4293644
    Abstract: Mutant which is used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to yield predominantly androst-4-ene-3,17-dione (AD) and small amounts of androsta-1,4-diene-3,17-dione (ADD). AD is a valuable intermediate to make useful steroids.
    Type: Grant
    Filed: October 9, 1977
    Date of Patent: October 6, 1981
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs
  • Patent number: 4293645
    Abstract: Mutants which are used in a novel microbiological process to selectively degrade steroids having 17-alkyl side chains of from 2 to 10 carbon atoms, inclusive, to androsta-1,4-diene-3,17-dione (ADD) and androst-4-ene-3,17-dione (AD). ADD and AD are valuable intermediates to make useful steroids.
    Type: Grant
    Filed: November 9, 1977
    Date of Patent: October 6, 1981
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Candice B. Biggs, Thomas R. Pyke
  • Patent number: 4175006
    Abstract: Valuable steroid intermediates, 9.alpha.-hydroxyandrost-4-ene-17.beta.-ol-3-one (9.alpha.--OH testosterone), 9.alpha.-hydroxy-3-ketobisnorchol-4-en-22-ol (9.alpha.--OH BN alcohol) and 9.alpha.---hydroxy-3-ketobisnorchol-4-en-22-oic methyl ester (9.alpha.--OH BN acid methyl ester), prepared by microbiological conversion of steroids having 17-alkyl side chains of 8 to 10 carbons.
    Type: Grant
    Filed: October 21, 1977
    Date of Patent: November 20, 1979
    Assignee: The Upjohn Company
    Inventors: Merle G. Wovcha, Frederick J. Antosz, John M. Beaton, Alfred B. Garcia, Leo A. Kominek